NasdaqCM - Nasdaq Real Time Price USD
Agenus Inc. (AGEN)
As of 11:24 AM EDT. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 3 | 5 |
| Avg. Estimate | -2.33 | -2.01 | -10.3 | -9.69 |
| Low Estimate | -2.89 | -2.89 | -14.25 | -12.59 |
| High Estimate | -0.9 | 0.58 | -6.27 | -5.52 |
| Year Ago EPS | -3.2 | -2.6 | -13.8 | -10.3 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 33.48M | 41.38M | 126.36M | 126.41M |
| Low Estimate | 23.5M | 23.5M | 98.5M | 100M |
| High Estimate | 58M | 98.4M | 207.9M | 175.63M |
| Year Ago Sales | 24.31M | 83.8M | 156.31M | 126.36M |
| Sales Growth (year/est) | 37.70% | -50.60% | -19.20% | 0.00% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -3.84 | -1.05 | -3.22 | -1.44 |
| EPS Actual | -3.2 | -2.6 | -3.04 | -2.52 |
| Difference | 0.64 | -1.55 | 0.18 | -1.08 |
| Surprise % | 16.70% | -147.60% | 5.60% | -75.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -2.33 | -2.01 | -10.3 | -9.69 |
| 7 Days Ago | -2.33 | -2.01 | -10.3 | -9.69 |
| 30 Days Ago | -2.33 | -2.01 | -10.3 | -9.69 |
| 60 Days Ago | -2.33 | -2.01 | -10.3 | -9.69 |
| 90 Days Ago | -2.14 | -2.23 | -8.87 | -9.57 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | AGEN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 27.20% | -- | -- | 5.10% |
| Next Qtr. | 22.70% | -- | -- | 11.80% |
| Current Year | 25.40% | -- | -- | 2.10% |
| Next Year | 5.90% | -- | -- | 12.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.68% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Maintains | B. Riley Securities: Buy to Buy | 8/14/2024 |
| Downgrade | Jefferies: Buy to Hold | 7/19/2024 |
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 7/18/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 6/28/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/24/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/7/2024 |
Related Tickers
INKT MiNK Therapeutics, Inc.
0.7199
+0.83%
CHRS Coherus BioSciences, Inc.
0.7380
-0.94%
BCRX BioCryst Pharmaceuticals, Inc.
8.15
+1.75%
XLO Xilio Therapeutics, Inc.
1.2200
-3.94%
PRAX Praxis Precision Medicines, Inc.
70.12
+0.19%
MGNX MacroGenics, Inc.
3.8900
+6.29%
CLDX Celldex Therapeutics, Inc.
25.98
-0.31%
BLUE bluebird bio, Inc.
0.4668
+0.60%
ATNM Actinium Pharmaceuticals, Inc.
1.8450
+2.50%
FATE Fate Therapeutics, Inc.
2.4150
+1.90%